Quick Answer
Vera Therapeutics, Inc. reported R&D Expense of $215.26 million for fiscal year 2025.
Vera Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $215.26M | +70.6% |
| 2024 | $126.17M | +61.3% |
| 2023 | $78.22M | +13.4% |
| 2022 | $68.99M | +206.9% |
| 2021 | $22.48M | -50.3% |
| 2020 | $45.21M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.47M | +40.1% | -3.0% |
| June 30, 2025 | $58.20M | +98.5% | +41.0% |
| March 31, 2025 | $41.28M | +77.9% | +2.4% |
| September 30, 2024 | $40.31M | +150.4% | +37.5% |
| June 30, 2024 | $29.31M | +80.6% | +26.3% |
| March 31, 2024 | $23.20M | -7.6% | +44.1% |
| September 30, 2023 | $16.10M | -18.1% | -0.8% |
| June 30, 2023 | $16.23M | +60.5% | -35.4% |
- Vera Therapeutics, Inc. showed an increase of +70.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Vera Therapeutics, Inc.’s r&d expense has grown by 376.2% (from $45.21 million to $215.26 million).
- The most recent figure is from Vera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: